Overview

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Treatments:

Antiviral Agents
Ribavirin
Ritonavir